Skip to main content

Phio Pharmaceuticals Corp.

PHIO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001533040

In the last 90 days, Phio Pharmaceuticals Corp. insiders filed 5 open-market purchases and 0 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $662.6K in total; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding Phio Pharmaceuticals Corp. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of PHIO: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders1617+1
Shares500.7K700.4K+199.7K (+39.9%)
Value$1.34M$1.58M+$240.0K (+17.9%)

New holders (6)

Institutions that held Phio Pharmaceuticals Corp. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to PHIO in Q2 2021
InstitutionSharesValue% of portfolio
Two Sigma Investments, LP41,873$95.0K0.00%
Goldman Sachs Group Inc19,002$43.0K0.00%
Two Sigma Securities, LLC17,099$39.0K0.01%
Millennium Management LLC10,035$23.0K0.00%
UBS Group AG1,377$3.00K0.00%
Tower Research Capital LLC (TRC)684$2.00K0.00%

Sold out (5)

Institutions that held Phio Pharmaceuticals Corp. at the end of Q1 2021 and filed for Q2 2021 without it.

Institutions that sold out of PHIO in Q2 2021
InstitutionShares, Q1 2021Value, Q1 2021
Gsa Capital Partners LLP132,333$355.0K
Susquehanna Fundamental Investments, LLC17,800$48.0K
Valeo Financial Advisors, LLC4,000$11.0K
Spire Wealth Management2,000$6.00K
Total Clarity Wealth Management, Inc.1,500$4.00K